Which of the following statements would indicate that a patient understands why he is taking Olumiant?
a. "I have vasomotor symptoms associated with menopause."
b. "I have rheumatoid arthritis."
c. "I have hypercalcemia."
d. "I have Paget's disease of bone."
e. "I have migraine headaches associated with menopause."
Answer: b
The active ingredient found in Olumiant is Baricitinib. It is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.
The recommended dose of Olumiant is 2 mg once daily.
Upper respiratory tract infections, nausea, herpes simplex, and herpes zoster are commonly reported side effects of the drug.
The drug also has shown promising result for the treatment of Covid-19 infection when administered simultaneously with Remdesivir.Olumiant (Baricitinib) in combination with Veklury (Remdesivir) cuts the median recovery time by about a day, compared to patients treated with Remdesivir alone.